Acrivon Therapeutics Inc

Business Description

Acrivon Therapeutics is a clinical-stage company focused on developing cancer treatments matched to the patients most likely to respond to them. It uses a proprietary proteomics platform to build companion diagnostic tools that help identify which tumors are sensitive to each specific drug. Its most advanced drug candidate, ACR-368, targets key proteins involved in DNA damage response and is being studied in patients with endometrial cancer, platinum-resistant ovarian cancer, and certain head and neck and anal cancers. The company, founded in 2018 and headquartered in Watertown, Massachusetts, is also advancing a second drug candidate and an early-stage cell cycle research program.